Attorney Profile:

Justin Chivinski

JC

Biography

Justin Chivinski practices in the area of corporate law. Mr. Chivinski is a 2013 graduate of Duke University School of Law and a graduate of the Pennsylvania State University.

Admissions

•Pennsylvania

Education

•Duke University School of Law, J.D., 2013
•The Pennsylvania State University, B.S., Finance, 2007

Experience

•Duane Morris LLP
- Associate, 2013-present

Education & Credentials

Contact Information:
215 979 1922  Phone
215 754 4962  Fax
www.duanemorris.com/attorneys/justinchivinski.html
University Attended:
The Pennsylvania State University, B.S., Finance, 2007
Law School Attended:
Duke University School of Law, J.D., 2013
Admission:
2013, Pennsylvania
Reported Cases:
Representative Matters: Represented Iroko Pharmaceuticals, LLC in connection with a $140 million secured loan facility with CRG, a healthcare investment fund, and the simultaneous pay-off of Iroko's loan facility with another lender.; Represented a dermatological pharmaceutical company that is developing a drug, presently in Phase IIa, for the treatment of various cutaneous inflammatory disorders, in a $5 million venture loan.; Represented Unilife Corp. (NASDAQ: UNIS / ASX: UNS) in connection with its announced effort to seek strategic alternatives, culminating in a strategic collaboration with Amgen Inc. (NASDAQ: AMGN) for Unilife's wearable injectable drug delivery systems to use with Amgen's biologics and other medicines. The deal provides Unilife with investments of up to $90 million from Amgen and restructures Unilife's existing debt with OrbiMed.; Represented Clarion Capital Partners and its portfolio company, HR Outsourcing Holdings, Inc., a professional employer organization based in Atlanta, Georgia, in the acquisition of the outstanding capital stock of Fortune Financial, Inc., another professional employer organization based in Tampa, Florida, as well as the related financing transaction.; Represented Velicept Therapeutics, a specialty pharmaceutical company, in its acquisition of AltheRx, Inc. and $20 million Series B financing.; Represented a derm-focused pharmaceutical company in connection with the closings of two rounds of Series A-2 Preferred Stock to Third Point, New Science Ventures and Palo Alto, all venture capital firms active in the pharmaceutical space, for a cumulative total of $10 million.; Represented the owners of a construction management and consulting company, in the sale of all of the membership interests to a subsidiary of a NYSE listed global provider of architecture, design, engineering, and construction services.; Represented Vonage Holdings Corp. in its acquisition of gUnify, Inc., a cloud-based technology company whose middleware solution integrates the Company's cloud communications platform with widely used SaaS business applications, including Google for Work, Zendesk, Salesforce's Sales Cloud, Clio, and other CRM solutions.; Represented a pain-focused pharmaceutical company in closing a $30 million venture loan. The lender is an investment firm dedicated to the healthcare sector.; Represented Aclaris Therapeutics, Inc., a specialty pharmaceutical company with a focus on the development of novel topical dermatological therapies, in connection with the sale of $21.3 million of Series B Preferred Stock.; Represented Current Analysis, Inc., an IT and telecom market-research firm, in the sale of the company to Progressive Digital Media Group through a merger transaction for a purchase price of $19.6 million.; Represented BeachGlow: Concerts for Charity, Inc., a non-profit concert producer, in helping the organization incorporate, obtain tax exempt status and negotiate various contracts pertaining to a concert.; Represented Ludwig Bohler in the sale of his interests in Bohler Engineering, P.C. and a series of affiliated entities to employees who collectively owned most of the interests in the acquired entities not previously owned directly or indirectly by Mr. Bohler.; Represented Iroko Pharmaceuticals, a global specialty pharmaceutical company dedicated to advancing the science of responsible pain management, in securing $75 million in debt financing to support general business operations and the commercialization of Iroko's FDA-approved ZORVOLEX (diclofenac), a drug that uses iCeutica Inc.'s proprietary SoluMatrix Fine Particle Technology to both reduce the dosage of active ingredients ingested by the patient and accelerate the dissolution of the drug in the patient.; Represented Alexar Therapeutics, Inc., a newly formed derm-focused pharmaceutical company, in connection with the sale of $21.5 million of Series A-1 and Series A-2 Preferred Stock to Third Point, New Science Ventures and Palo Alto, venture capital firms active in the pharmaceutical space, and the simultaneous closing of the purchase of the stock of Anayaderm, a development-stage pharmaceutical company.; Represented a French media and sports management company in connection with the acquisition by its U.S. subsidiary of a golf events management company.
ISLN:
922684549

Peer Reviews

This lawyer does not have peer reviews.

*Peer Reviews provided before April 15, 2008 are not displayed.

Client Reviews

Disclaimer

Documents ({{amountArticles}})

Documents by this lawyer on Martindale.com
Other documents: ,

Locations

Contact Justin Chivinski

Please correct the fields highlighted in red.

By clicking on the "Submit" button, you agree to the Terms of Use, Supplemental Terms and Privacy Policy. You also consent to be contacted at the phone number you provided, including by autodials, text messages and/or pre-recorded calls, from Martindale and its affiliates and from or on behalf of attorneys you request or contact through this site. Consent is not a condition of purchase.


You should not send any sensitive or confidential information through this site. Emails sent through this site do not create an attorney-client relationship and may not be treated as privileged or confidential. The lawyer or law firm you are contacting is not required to, and may choose not to, accept you as a client. The Internet is not necessarily secure and emails sent though this site could be intercepted or read by third parties.